These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

859 related items for PubMed ID: 29031784

  • 1. Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.
    Yao X, Xia F, Tang W, Xiao C, Yang M, Zhou B.
    J Ethnopharmacol; 2018 Feb 15; 212():208-215. PubMed ID: 29031784
    [Abstract] [Full Text] [Related]

  • 2. Isobaric Tags for Relative and Absolute Quantitation (iTRAQ)-Based Proteomic Analysis of Hugan Qingzhi and Its Protective Properties against Free Fatty Acid-Induced L02 Hepatocyte Injury.
    Xia F, Yao X, Tang W, Xiao C, Yang M, Zhou B.
    Front Pharmacol; 2017 Feb 15; 8():99. PubMed ID: 28293193
    [Abstract] [Full Text] [Related]

  • 3. Hugan Qingzhi tablets attenuates endoplasmic reticulum stress in nonalcoholic fatty liver disease rats by regulating PERK and ATF6 pathways.
    Yang M, Yao X, Xia F, Xiang S, Tang W, Zhou B.
    BMC Complement Med Ther; 2024 Jan 12; 24(1):36. PubMed ID: 38216941
    [Abstract] [Full Text] [Related]

  • 4. Modulation of the Gut Microbiota in Rats by Hugan Qingzhi Tablets during the Treatment of High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease.
    Tang W, Yao X, Xia F, Yang M, Chen Z, Zhou B, Liu Q.
    Oxid Med Cell Longev; 2018 Jan 12; 2018():7261619. PubMed ID: 30671174
    [Abstract] [Full Text] [Related]

  • 5. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
    Yin J, Luo Y, Deng H, Qin S, Tang W, Zeng L, Zhou B.
    J Ethnopharmacol; 2014 May 28; 154(1):229-39. PubMed ID: 24735863
    [Abstract] [Full Text] [Related]

  • 6. [Effect of Hugan Qingzhi tablets on AMPK pathway activation and NF-κB-p65 protein expression in the liver of rats with nonalcoholic fatty liver disease].
    Yao XR, Xia F, Tang WJ, Zhou BJ.
    Nan Fang Yi Ke Da Xue Xue Bao; 2017 Jan 20; 37(1):56-62. PubMed ID: 28109099
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y, Chen L, Wang H, Narisi B, Chen B.
    J Ethnopharmacol; 2015 Dec 24; 176():499-507. PubMed ID: 26571089
    [Abstract] [Full Text] [Related]

  • 12. Chaihu Shugan powder influences nonalcoholic fatty liver disease in rats in remodeling microRNAome and decreasing fatty acid synthesis.
    Zheng C, Nie H, Pan M, Fan W, Pi D, Liang Z, Liu D, Wang F, Yang Q, Zhang Y.
    J Ethnopharmacol; 2024 Jan 10; 318(Pt A):116967. PubMed ID: 37506783
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
    Zhang R, Yu Y, Hu S, Zhang J, Yang H, Han B, Cheng Y, Luo X.
    Nutr Res; 2016 Sep 10; 36(9):1022-1030. PubMed ID: 27632923
    [Abstract] [Full Text] [Related]

  • 15. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
    Zhang Y, Tang K, Deng Y, Chen R, Liang S, Xie H, He Y, Chen Y, Yang Q.
    Biomed Pharmacother; 2018 Jun 10; 102():1025-1036. PubMed ID: 29710519
    [Abstract] [Full Text] [Related]

  • 16. Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway.
    Zhang YP, Deng YJ, Tang KR, Chen RS, Liang S, Liang YJ, Han L, Jin L, Liang ZE, Chen YN, Yang QH.
    Curr Med Sci; 2019 Feb 10; 39(1):37-43. PubMed ID: 30868489
    [Abstract] [Full Text] [Related]

  • 17. Comparative proteomic analysis using 2DE-LC-MS/MS reveals the mechanism of Fuzhuan brick tea extract against hepatic fat accumulation in rats with nonalcoholic fatty liver disease.
    Liu Z, Lin Y, Zhang S, Wang D, Liang Q, Luo G.
    Electrophoresis; 2015 Sep 10; 36(17):2002-16. PubMed ID: 26036873
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Shenling Baizhu powder alleviates non-alcoholic fatty liver disease by modulating autophagy and energy metabolism in high-fat diet-induced rats.
    Pan M, Deng Y, Qiu Y, Pi D, Zheng C, Liang Z, Zhen J, Fan W, Song Q, Pan J, Li Y, Yan H, Yang Q, Zhang Y.
    Phytomedicine; 2024 Jul 25; 130():155712. PubMed ID: 38763008
    [Abstract] [Full Text] [Related]

  • 20. Integrated network pharmacology, metabolomics, and transcriptomics of Huanglian-Hongqu herb pair in non-alcoholic fatty liver disease.
    Zhang X, Zhang J, Zhou Z, Xiong P, Cheng L, Ma J, Wen Y, Shen T, He X, Wang L, Zhang Y, Xiao C.
    J Ethnopharmacol; 2024 May 10; 325():117828. PubMed ID: 38325669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.